Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dean A Regier

Showing results (51-60 of 124) with videos related to

Pageof 13
Sort By:
Healthcare Management Forum|October 25, 2019
Evidence, values, and funding decisions in Canadian cancer systemsStuart J Peacock, Dean A Regier, Adam J N Raymakers, et al.
Journal of Managed Care & Specialty Pharmacy|April 1, 2020
Payer Preferences and Willingness to Pay for Genomic Precision Medicine: A Discrete Choice ExperimentDevender S Dhanda, David L Veenstra, Dean A Regier, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 16, 2014
Parents' willingness to pay for biologic treatments in juvenile idiopathic arthritisHeather F Burnett, Wendy J Ungar, Dean A Regier, et al.
Arthritis Care & Research|April 17, 2012
Parents' preferences for drug treatments in juvenile idiopathic arthritis: a discrete choice experimentHeather F Burnett, Dean A Regier, Brian M Feldman, et al.
Journal of Health Services Research & Policy|April 27, 2012
Response to 'Marginal costs of hospital-acquired conditions: information for priority-setting for patient safety programmes and research', Jackson et al., Journal of Health Services Research & Policy 2011;16:141-6Corneliu Bolbocean, Dean A Regier, Nick Bansback, et al.
CMAJ Open|July 29, 2018
Cancer drug expenditure in British Columbia and Saskatchewan: a trend analysisReka Pataky, David A Tran, Andrea Coronado, et al.
Pharmacoeconomics|January 19, 2021
Early-Phase Clinical Trials and Reimbursement Submissions to the Pan-Canadian Oncology Drug ReviewAdam J N Raymakers, Kristina M Jenei, Dean A Regier, et al.
Health Expectations : an International Journal of Public Participation in Health Care and Health Policy|April 28, 2020
Genetic testing for hereditary cancer syndromes: patient recommendations for improved risk communicationSamantha Pollard, Steve Kalloger, Deirdre Weymann, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 19, 2018
Using "Big Data" in the Cost-Effectiveness Analysis of Next-Generation Sequencing Technologies: Challenges and Potential SolutionsSarah Wordsworth, Brett Doble, Katherine Payne, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 12, 2020
Addressing Challenges of Economic Evaluation in Precision Medicine Using Dynamic Simulation ModelingDeborah A Marshall, Luiza R Grazziotin, Dean A Regier, et al.
Pageof 13

Showing results (51-60 of 124) with videos related to

Sort By:
Pageof 13
Healthcare Management Forum|October 25, 2019
Evidence, values, and funding decisions in Canadian cancer systemsStuart J Peacock, Dean A Regier, Adam J N Raymakers, et al.
Journal of Managed Care & Specialty Pharmacy|April 1, 2020
Payer Preferences and Willingness to Pay for Genomic Precision Medicine: A Discrete Choice ExperimentDevender S Dhanda, David L Veenstra, Dean A Regier, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 16, 2014
Parents' willingness to pay for biologic treatments in juvenile idiopathic arthritisHeather F Burnett, Wendy J Ungar, Dean A Regier, et al.
Arthritis Care & Research|April 17, 2012
Parents' preferences for drug treatments in juvenile idiopathic arthritis: a discrete choice experimentHeather F Burnett, Dean A Regier, Brian M Feldman, et al.
Journal of Health Services Research & Policy|April 27, 2012
Response to 'Marginal costs of hospital-acquired conditions: information for priority-setting for patient safety programmes and research', Jackson et al., Journal of Health Services Research & Policy 2011;16:141-6Corneliu Bolbocean, Dean A Regier, Nick Bansback, et al.
CMAJ Open|July 29, 2018
Cancer drug expenditure in British Columbia and Saskatchewan: a trend analysisReka Pataky, David A Tran, Andrea Coronado, et al.
Pharmacoeconomics|January 19, 2021
Early-Phase Clinical Trials and Reimbursement Submissions to the Pan-Canadian Oncology Drug ReviewAdam J N Raymakers, Kristina M Jenei, Dean A Regier, et al.
Health Expectations : an International Journal of Public Participation in Health Care and Health Policy|April 28, 2020
Genetic testing for hereditary cancer syndromes: patient recommendations for improved risk communicationSamantha Pollard, Steve Kalloger, Deirdre Weymann, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 19, 2018
Using "Big Data" in the Cost-Effectiveness Analysis of Next-Generation Sequencing Technologies: Challenges and Potential SolutionsSarah Wordsworth, Brett Doble, Katherine Payne, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 12, 2020
Addressing Challenges of Economic Evaluation in Precision Medicine Using Dynamic Simulation ModelingDeborah A Marshall, Luiza R Grazziotin, Dean A Regier, et al.
Pageof 13